vvax001
Vaccineexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 13, 2017 (NCT03141463)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- vvax001
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06015854 | Phase 2 | Mar 23, 2021 | Dutch Cancer Society, University of Groningen, ViciniVax B.V |
| NCT03141463 | Phase 1 | Jan 13, 2017 | Dutch Cancer Society, University of Groningen, ViciniVax B.V |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Dutch Cancer Society | Academic/Hospital | 2 | 0 | 2 | 2017 |
| University of Groningen | Academic/Hospital | 2 | 2 | 2 | 2017 |
| ViciniVax B.V | For profit | 2 | 0 | 2 | 2017 |
3 organizations
Page 1 / 1